share_log

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8：員工福利計劃證券登記
美股SEC公告 ·  12/13 05:13

Moomoo AI 已提取核心訊息

Adial Pharmaceuticals has filed a Form S-8 registration statement to add 1.5 million shares of common stock to its 2017 Equity Incentive Plan. This addition was approved by the company's board and shareholders at the 2024 Annual Meeting on November 12, 2024, as part of Amendment No. 6 to the plan.The registration increases the total number of shares available under the plan to 2 million. This follows previous amendments and a 1-for-25 reverse stock split effected on August 4, 2023. The additional shares are intended to provide equity incentives to employees, directors and consultants.The filing incorporates by reference Adial's recent SEC filings, including its 2023 annual report and 2024 quarterly reports. It also outlines standard indemnification provisions for directors and officers as permitted under Delaware law.
Adial Pharmaceuticals has filed a Form S-8 registration statement to add 1.5 million shares of common stock to its 2017 Equity Incentive Plan. This addition was approved by the company's board and shareholders at the 2024 Annual Meeting on November 12, 2024, as part of Amendment No. 6 to the plan.The registration increases the total number of shares available under the plan to 2 million. This follows previous amendments and a 1-for-25 reverse stock split effected on August 4, 2023. The additional shares are intended to provide equity incentives to employees, directors and consultants.The filing incorporates by reference Adial's recent SEC filings, including its 2023 annual report and 2024 quarterly reports. It also outlines standard indemnification provisions for directors and officers as permitted under Delaware law.
Adial Pharmaceuticals已提交S-8表格註冊聲明，以向其2017年股權激勵計劃增加150萬股普通股。這項增補在2024年11月12日的年度股東大會上得到了公司董事會和股東的批准，作爲該計劃第六次修訂的一部分。此註冊使得該計劃下可用的股份總數增加到200萬股。這一增補是在之前修訂和2023年8月4日實施的1拆25的反向股票分割之後進行的。額外的股份旨在爲員工、董事和顧問提供股權激勵。該提交通過引用Adial最近的SEC文件，包括其2023年年度報告和2024年季度報告。它還概述了德拉瓦州法律允許的針對董事和高管的標準賠償條款。
Adial Pharmaceuticals已提交S-8表格註冊聲明，以向其2017年股權激勵計劃增加150萬股普通股。這項增補在2024年11月12日的年度股東大會上得到了公司董事會和股東的批准，作爲該計劃第六次修訂的一部分。此註冊使得該計劃下可用的股份總數增加到200萬股。這一增補是在之前修訂和2023年8月4日實施的1拆25的反向股票分割之後進行的。額外的股份旨在爲員工、董事和顧問提供股權激勵。該提交通過引用Adial最近的SEC文件，包括其2023年年度報告和2024年季度報告。它還概述了德拉瓦州法律允許的針對董事和高管的標準賠償條款。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間